Sugi Predict

Sugi Predict / Compounds / SCHEMBL3475291

SCHEMBL3475291

SCHEMBL3475291

O=C(O)Nc1c(F)ccc(Cl)c1F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 1/20 0.42
▸ KMT2A Q03164 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ SORT1 Q99523 1/20 0.38
▸ S1PR4 O95977 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ MAPT P10636 1/20 0.35
▸ RPA1 P27694 1/20 0.35
▸ BTK Q06187 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14691471 0.85 GPR35 (0.42) SLC2A1KMT2ANPC1RAB9AMEN1
SCHEMBL16176623 0.83 SORT1 (0.37) SLC2A1LMNASORT1ALDH1A1
SCHEMBL29739584 0.80 SMN1; SMN2 (0.40) SLC2A1KMT2ANPC1RAB9AMEN1
SCHEMBL28297911 0.77 KMT2A (0.47) KMT2ANPC1RAB9AMEN1LMNA
SCHEMBL29739401 0.77 KMT2A (0.47) KMT2ANPC1RAB9AMEN1LMNA
SCHEMBL20577762 0.77 HDAC1 (0.37) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL1494522 0.77 KMT2A (0.37) KMT2ANPC1RAB9AMEN1LMNA
SCHEMBL17398559 0.76 TRPV1 (0.36) LMNASORT1TSHRALDH1A1
SCHEMBL3912399 0.74 FABP4 (0.44) KMT2ANPC1RAB9AMEN1LMNA
SCHEMBL26928415 0.74 SMN1; SMN2 (0.41) KMT2ANPC1RAB9AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240083869-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2024-03-14 — — US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
CN-117242060-A Isoindolinone compounds 蒙特罗萨医疗公司 2023-12-15 — — CN disclosed
EP-4277901-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
EP-4278014-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS Monte Rosa Therapeutics, Inc. (US) 2023-11-22 — — EP disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 — — US disclosed
WO-2022152822-A1 TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS MONTE ROSA THERAPEUTICS AG (CH) 2022-07-21 — — WO disclosed
WO-2022152821-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-07-21 — — WO disclosed
US-10208068-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-19 — — US disclosed
US-20180148461-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-05-31 — — US disclosed
US-20160068544-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-03-10 — — US disclosed
US-9221818-B2 Macrocycles as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-29 — — US disclosed
US-20140221338-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-07 — — US disclosed
EP-2739628-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS Bristol-Myers Squibb Company (US) 2014-06-11 — — EP disclosed
US-8697737-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2014-04-15 — — US disclosed
WO-2013022818-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2013-02-14 — — WO disclosed
US-7846959-B2 Raf modulators and methods of use EXELIXIS, INC. (US) 2010-12-07 — — US disclosed
US-20080009488-A1 Raf Modulators and Methods of Use EXELIXIS, INC. (US) 2008-01-10 — — US disclosed
EP-1751124-A2 RAF MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 — — EP disclosed
WO-2005112932-A2 RAF MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148461-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 SLC2A1 4105/4885KMT2A 1182/4885NPC1 2191/4885
US-20080009488-A1 Raf Modulators and Methods of Use BRAF, RAF1, ARAF SLC2A1 998/4885KMT2A 2385/4885NPC1 2107/4885
US-10208068-B2 Macrocycles as factor XIa inhibitors TFPI, TFPI2, F12 SLC2A1 3753/4885KMT2A 1029/4885NPC1 1981/4885
US-20160068544-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 SLC2A1 4105/4885KMT2A 1182/4885NPC1 2191/4885
US-20240083869-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 SLC2A1 2230/4885KMT2A 1951/4885NPC1 285/4885
US-20140221338-A1 NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F12 SLC2A1 4105/4885KMT2A 1182/4885NPC1 2191/4885
US-20230348418-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 SLC2A1 2215/4885KMT2A 1988/4885NPC1 269/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 SLC2A1 2230/4885KMT2A 1951/4885NPC1 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.